Literature DB >> 25712213

Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors.

Sofia Lourenco1, Vitor H Teixeira2, Tammy Kalber3, Ricardo J Jose4, R Andres Floto5, Sam M Janes2.   

Abstract

Mesenchymal stromal cells (MSCs) are inherently tumor homing and can be isolated, expanded, and transduced, making them viable candidates for cell therapy. This tumor tropism has been used to deliver anticancer therapies to various tumor models. In this study, we sought to discover which molecules are the key effectors of human MSC tumor homing in vitro and using an in vivo murine model. In this study, we discover a novel role for macrophage migration inhibitory factor (MIF) as the key director of MSC migration and infiltration toward tumor cells. We have shown this major role for MIF using in vitro migration and invasion assays, in presence of different receptor inhibitors and achieving a drastic decrease in both processes using MIF inhibitor. Additionally, we demonstrate physical interaction between MIF and three receptors: CXCR2, CXCR4, and CD74. CXCR4 is the dominant receptor used by MIF in the homing tumor context, although some signaling is observed through CXCR2. We demonstrate downstream activation of the MAPK pathway necessary for tumor homing. Importantly, we show that knockdown of either CXCR4 or MIF abrogates MSC homing to tumors in an in vivo pulmonary metastasis model, confirming the in vitro two-dimensional and three-dimensional assays. This improved understanding of MSC tumor tropism will further enable development of novel cellular therapies for cancers.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25712213      PMCID: PMC4374168          DOI: 10.4049/jimmunol.1402097

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.

Authors:  Yoonsang Cho; Gregg V Crichlow; Jon J Vermeire; Lin Leng; Xin Du; Michael E Hodsdon; Richard Bucala; Michael Cappello; Matt Gross; Federico Gaeta; Kirk Johnson; Elias J Lolis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-08       Impact factor: 11.205

Review 2.  CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.

Authors:  Federica Borghese; Felix I L Clanchy
Journal:  Expert Opin Ther Targets       Date:  2011-01-06       Impact factor: 6.902

3.  The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.

Authors:  Roderick J Phillips; Marie D Burdick; Marin Lutz; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  Am J Respir Crit Care Med       Date:  2003-03-05       Impact factor: 21.405

4.  Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis.

Authors:  Anke Burger-Kentischer; Heike Goebel; Rüdiger Seiler; Gustav Fraedrich; Hans E Schaefer; Stefanie Dimmeler; Robert Kleemann; Jürgen Bernhagen; Christian Ihling
Journal:  Circulation       Date:  2002-04-02       Impact factor: 29.690

5.  Differential gene expression profiling in human brain tumors.

Authors:  J M Markert; C M Fuller; G Y Gillespie; J K Bubien; L A McLean; R L Hong; K Lee; S R Gullans; T B Mapstone; D J Benos
Journal:  Physiol Genomics       Date:  2001-02-07       Impact factor: 3.107

6.  Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

Authors:  Yan-Xi Sun; Jingcheng Wang; Charles E Shelburne; Dennis E Lopatin; Arul M Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

7.  Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells.

Authors:  R M Dwyer; S M Potter-Beirne; K A Harrington; A J Lowery; E Hennessy; J M Murphy; F P Barry; T O'Brien; M J Kerin
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

8.  IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival.

Authors:  Inbal Binsky; Michal Haran; Diana Starlets; Yael Gore; Frida Lantner; Nurit Harpaz; Lin Leng; David M Goldenberg; Lev Shvidel; Alain Berrebi; Richard Bucala; Idit Shachar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-08       Impact factor: 11.205

9.  Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung.

Authors:  Susana Aguilar; Emma Nye; Jerry Chan; Michael Loebinger; Bradley Spencer-Dene; Nick Fisk; Gordon Stamp; Dominique Bonnet; Sam M Janes
Journal:  Stem Cells       Date:  2007-03-15       Impact factor: 6.277

10.  Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association.

Authors:  Pedro L Vera; Kenneth A Iczkowski; Xihai Wang; Katherine L Meyer-Siegler
Journal:  PLoS One       Date:  2008-12-10       Impact factor: 3.240

View more
  53 in total

Review 1.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

Review 2.  Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?

Authors:  Ann De Becker; Ivan Van Riet
Journal:  World J Stem Cells       Date:  2016-03-26       Impact factor: 5.326

Review 3.  Mesenchymal Stem Cells on Horizon: A New Arsenal of Therapeutic Agents.

Authors:  Zahra Abbasi-Malati; Amaneh Mohammadi Roushandeh; Yoshikazu Kuwahara; Mehryar Habibi Roudkenar
Journal:  Stem Cell Rev Rep       Date:  2018-08       Impact factor: 5.739

4.  Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.

Authors:  Suhendan Ekmekcioglu; Michael A Davies; Keiji Tanese; Jason Roszik; Myung Shin-Sim; Roland L Bassett; Denái R Milton; Scott E Woodman; Victor G Prieto; Jeffrey E Gershenwald; Donald L Morton; Dave S Hoon; Elizabeth A Grimm
Journal:  Clin Cancer Res       Date:  2016-01-18       Impact factor: 12.531

Review 5.  Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis.

Authors:  Yang Guo; Bo Chen; Li-Jun Chen; Chun-Feng Zhang; Charlie Xiang
Journal:  J Zhejiang Univ Sci B       Date:  2016 Nov.       Impact factor: 3.066

Review 6.  Mesenchymal stem cells: From regeneration to cancer.

Authors:  Peishan Li; Zheng Gong; Leonard D Shultz; Guangwen Ren
Journal:  Pharmacol Ther       Date:  2019-04-16       Impact factor: 12.310

Review 7.  Stem cell-based therapies for tumors in the brain: are we there yet?

Authors:  Khalid Shah
Journal:  Neuro Oncol       Date:  2016-06-09       Impact factor: 12.300

Review 8.  The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication.

Authors:  Laura MacDonald; Jonathan Jenkins; Grace Purvis; Joshua Lee; Aime T Franco
Journal:  Horm Cancer       Date:  2020-06-17       Impact factor: 3.869

Review 9.  Interplay between mesenchymal stem cell and tumor and potential application.

Authors:  Qing Wang; Ti Li; Wei Wu; Gang Ding
Journal:  Hum Cell       Date:  2020-05-06       Impact factor: 4.174

10.  Regional Hyperthermia Enhances Mesenchymal Stem Cell Recruitment to Tumor Stroma: Implications for Mesenchymal Stem Cell-Based Tumor Therapy.

Authors:  Mariella Tutter; Christina Schug; Kathrin A Schmohl; Sarah Urnauer; Carolin Kitzberger; Nathalie Schwenk; Matteo Petrini; Christian Zach; Sibylle Ziegler; Peter Bartenstein; Wolfgang A Weber; Gabriele Multhoff; Ernst Wagner; Lars H Lindner; Peter J Nelson; Christine Spitzweg
Journal:  Mol Ther       Date:  2020-10-15       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.